Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer

Monocyte chemoattractant protein-1 (MCP-1) is a chemokine which plays critical roles in regulating host immune responses. Researches have shown that MCP-1 may greatly participate in the development of different cancers. In the current study, we investigated the effect of MCP-1 on ovarian cancer by examining the association between MCP-1 genetic polymorphisms and the susceptibility to ovarian cancer. MCP-1 −2158A/G and MCP-1 −362C/G polymorphisms were examined in ovarian cancer patients and healthy controls by using polymerase chain reaction–restriction fragment length polymorphism analysis. Results showed that percentages of MCP-1 −2158GG genotype and G allele were significantly higher in ovarian cancer patients than in controls (odd ratio (OR) = 1.87; 95 % confidence interval (CI), 1.19–2.76; P = 0.012 and OR = 1.47; 95 % CI, 1.11–1.79; P = 0.003; data were adjusted for age and smoking status). The MCP-1 −362GG genotype also revealed increased number in patients. Stratification analyses presented that ovarian cancer cases with serous-papillary type had significantly increased percentage of −362GG genotype than those with other types (13.1 versus 5.0 %, P = 0.032; data were adjusted for age and smoking status). Also, we evaluated the relation between these two polymorphisms and serum level of MCP-1. We identified that the subjects with MCP-1 −2158AG and GG genotypes had clearly increased serum level of MCP-1 than those with AA genotype. These data suggest that MCP-1 may be involved in the pathogenesis of ovarian cancer.